• Explore /
  • Poster
  • / ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

Abstract Poster

Authors

Ignace Vergote

Ignace Vergote

BGOG and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium

Ignace Vergote , Jalid Sehouli , Vanda Salutari , Paolo Zola , Radoslaw Madry , Robert Michael Wenham , Jacob Korach , Patricia Pautier , David Cibula , Stephanie Lheureux , Kosei Hasegawa , Byoung-Gie Kim , Chyong-Huey Lai , Antonio González-Martín , Qi Liu , Stephen Michael Keefe , Martina Puglisi , Samet Topuz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03740165

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS5603)

DOI

10.1200/JCO.2019.37.15_suppl.TPS5603

Abstract #

TPS5603

Poster Bd #

421b

Abstract Disclosures

Similar Posters

First Author: Philipp Harter

First Author: Ronnie Shapira-Frommer

First Author: Anne-Claire Hardy-Bessard

First Author: Elena Ioana Braicu